Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:21:14.878Z.
Calculation as of: 2026-10-06T18:21:14.878Z.
Quote observation: 2026-10-06T18:09:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ec04a23f2eccb1c46d806cafb3c6508f31619b4012dc27c85b71ebd533873098
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.48M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | $1.47M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.46M | N/A | 0.69% | 0.69% | 0.69% |
| NEXGEL, Inc. (NXGL)vs › | $1.44M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.35M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.35M | N/A | N/A | N/A | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.34M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
